Company profile
Lobe Sciences Ltd.
OTC: LOBEF · Healthcare · Biotechnology
Canadian filerHQ Vancouver, BCReports USD
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
42DFH 45DQ —GM 43SS 22
v0.1 · 45/100 weight · provisional
↑ growth stability, balance-sheet leverage · ↓ revenue growth (YoY), listing tenure
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$3.2M
Employees
—
as of 2026-08-25
Market cap
$1.8M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$00 CAD2025
Net income-$3.2M-4.4M CAD2025
Operating income-$3.0M-4.2M CAD2025
Total assets$5.5M7.6M CAD2025
Liabilities$2.0M2.7M CAD2025
Equity$1.7M2.4M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Lobe Sciences Ltd.’s revenue?
Lobe Sciences Ltd. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Genprex, Inc.34DiMD Companies, Inc.47DTelo Genomics Corp.——Dakshidin Corporation31DDecoy Therapeutics Inc.31DProtagenic Therapeutics, Inc.——Key facts
CEOFrederick Dominick Sancilio
SectorHealthcare
IndustryBiotechnology
HeadquartersVancouver, BC
ExchangeOTC: LOBEF
Employees—
IPO date2023-08-24
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.